Title: Full Text of HB2584
Official Title: 
Number of Sections: 1
Source: versions - House Amendment 002
Media Type: text/html

================================================================================

Section 1:
Full Text of HB2584 ILGA.GOV HB2584 - 104th General Assembly Rep. Kelly M. CassidyFiled: 4/7/2025   10400HB2584ham002LRB104 08321 BAB 24919 a1AMENDMENT TO HOUSE BILL 25842    AMENDMENT NO. ______. Amend House Bill 2584, AS AMENDED, 3by replacing everything after the enacting clause with the 4following: 5    "Section 5. The Illinois Insurance Code is amended by 6changing Section 356z.60 as follows: 7    (215 ILCS 5/356z.60)8    Sec. 356z.60. Coverage for abortifacients, hormonal 9therapy, and human immunodeficiency virus pre-exposure 10prophylaxis and post-exposure prophylaxis.11    (a) As used in this Section:12    "Abortifacients" means any medication administered to 13terminate a pregnancy as prescribed or ordered by a health 14care professional.15    "Health care professional" means a physician licensed to 16practice medicine in all of its branches, licensed advanced   10400HB2584ham002- 2 -LRB104 08321 BAB 24919 a1practice registered nurse, or physician assistant.2    "Hormonal therapy medication" means hormonal treatment 3administered to treat gender dysphoria.4    "Therapeutic equivalent version" means drugs, devices, or 5products that can be expected to have the same clinical effect 6and safety profile when administered to patients under the 7conditions specified in the labeling and that satisfy the 8following general criteria:9        (1) it is approved as safe and effective;10        (2) it is a pharmaceutical equivalent in that it:11            (A) contains identical amounts of the same active 12        drug ingredient in the same dosage form and route of 13        administration; and14            (B) meets compendial or other applicable standards 15        of strength, quality, purity, and identity;16        (3) it is bioequivalent in that:17            (A) it does not present a known or potential 18        bioequivalence problem and it meets an acceptable in 19        vitro standard; or20            (B) if it does present such a known or potential 21        problem, it is shown to meet an appropriate 22        bioequivalence standard;23        (4) it is adequately labeled; and24        (5) it is manufactured in compliance with Current Good 25    Manufacturing Practice regulations adopted by the United 26    States Food and Drug Administration.  10400HB2584ham002- 3 -LRB104 08321 BAB 24919 a1    (b) An individual or group policy of accident and health 2insurance amended, delivered, issued, or renewed in this State 3on or after January 1, 2024 shall provide coverage for all 4abortifacients, hormonal therapy medication, human 5immunodeficiency virus pre-exposure prophylaxis, and 6post-exposure prophylaxis drugs approved by the United States 7Food and Drug Administration, and follow-up services related 8to that coverage, including, but not limited to, management of 9side effects, medication self-management or adherence 10counseling, risk reduction strategies, and mental health 11counseling. This coverage shall include drugs approved by the 12United States Food and Drug Administration that are prescribed 13or ordered for off-label use for the purposes described in 14this Section. On or after the effective date of this 15amendatory Act of the 104th General Assembly, this coverage 16shall include pre-PrEP HIV screening, sexually transmitted 17infection screening, kidney function analysis, routine 18laboratory testing, and routine provider visits. 19    (c) The coverage required under subsection (b) is subject 20to the following conditions:21        (1) If the United States Food and Drug Administration 22    has approved one or more therapeutic equivalent versions 23    of an abortifacient drug, a policy is not required to 24    include all such therapeutic equivalent versions in its 25    formulary so long as at least one is included and covered 26    without cost sharing and in accordance with this Section.  10400HB2584ham002- 4 -LRB104 08321 BAB 24919 a1        (2) If an individual's attending provider recommends a 2    particular drug approved by the United States Food and 3    Drug Administration based on a determination of medical 4    necessity with respect to that individual, the plan or 5    issuer must defer to the determination of the attending 6    provider and must cover that service or item without cost 7    sharing.8        (3) If a drug is not covered, plans and issuers must 9    have an easily accessible, transparent, and sufficiently 10    expedient process that is not unduly burdensome on the 11    individual or a provider or other individual acting as a 12    patient's authorized representative to ensure coverage 13    without cost sharing.14    The conditions listed under this subsection (c) also apply 15to drugs prescribed for off-label use as abortifacients. 16    (d) Except as otherwise provided in this Section, a policy 17subject to this Section shall not impose a deductible, 18coinsurance, copayment, or any other cost-sharing requirement 19on the coverage provided. The provisions of this subsection do 20not apply to coverage of procedures to the extent such 21coverage would disqualify a high-deductible health plan from 22eligibility for a health savings account pursuant to the 23federal Internal Revenue Code, 26 U.S.C. 223.24    (e) Except as otherwise authorized under this Section, a 25policy shall not impose any restrictions or delays on the 26coverage required under this Section.  10400HB2584ham002- 5 -LRB104 08321 BAB 24919 a1    (f) The coverage requirements in this Section for 2abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), 3apply to a multistate plan that does not provide coverage for 4abortion.5    (g) If the Department concludes that enforcement of any 6coverage requirement of this Section for abortifacients may 7adversely affect the allocation of federal funds to this 8State, the Department may grant an exemption to that 9requirement, but only to the minimum extent necessary to 10ensure the continued receipt of federal funds.11(Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.) 12    Section 10. The Prior Authorization Reform Act is amended 13by adding Section 52 as follows: 14    (215 ILCS 200/52 new)15    Sec. 52. Prior authorization for certain prescription 16drugs; prohibited. A health insurance issuer may not require 17prior authorization for the following prescription drug types 18and their therapeutic equivalents approved by the United 19States Food and Drug Administration: human immunodeficiency 20virus pre-exposure prophylaxis and post-exposure prophylaxis 21medication or human immunodeficiency virus treatment 22medication. 23    Section 99. Effective date. This Act takes effect January   10400HB2584ham002- 6 -LRB104 08321 BAB 24919 a11, 2027.".


================================================================================

Raw Text:
Full Text of HB2584 ILGA.GOV HB2584 - 104th General Assembly Rep. Kelly M. CassidyFiled: 4/7/2025   10400HB2584ham002LRB104 08321 BAB 24919 a1AMENDMENT TO HOUSE BILL 25842    AMENDMENT NO. ______. Amend House Bill 2584, AS AMENDED, 3by replacing everything after the enacting clause with the 4following: 5    "Section 5. The Illinois Insurance Code is amended by 6changing Section 356z.60 as follows: 7    (215 ILCS 5/356z.60)8    Sec. 356z.60. Coverage for abortifacients, hormonal 9therapy, and human immunodeficiency virus pre-exposure 10prophylaxis and post-exposure prophylaxis.11    (a) As used in this Section:12    "Abortifacients" means any medication administered to 13terminate a pregnancy as prescribed or ordered by a health 14care professional.15    "Health care professional" means a physician licensed to 16practice medicine in all of its branches, licensed advanced   10400HB2584ham002- 2 -LRB104 08321 BAB 24919 a1practice registered nurse, or physician assistant.2    "Hormonal therapy medication" means hormonal treatment 3administered to treat gender dysphoria.4    "Therapeutic equivalent version" means drugs, devices, or 5products that can be expected to have the same clinical effect 6and safety profile when administered to patients under the 7conditions specified in the labeling and that satisfy the 8following general criteria:9        (1) it is approved as safe and effective;10        (2) it is a pharmaceutical equivalent in that it:11            (A) contains identical amounts of the same active 12        drug ingredient in the same dosage form and route of 13        administration; and14            (B) meets compendial or other applicable standards 15        of strength, quality, purity, and identity;16        (3) it is bioequivalent in that:17            (A) it does not present a known or potential 18        bioequivalence problem and it meets an acceptable in 19        vitro standard; or20            (B) if it does present such a known or potential 21        problem, it is shown to meet an appropriate 22        bioequivalence standard;23        (4) it is adequately labeled; and24        (5) it is manufactured in compliance with Current Good 25    Manufacturing Practice regulations adopted by the United 26    States Food and Drug Administration.  10400HB2584ham002- 3 -LRB104 08321 BAB 24919 a1    (b) An individual or group policy of accident and health 2insurance amended, delivered, issued, or renewed in this State 3on or after January 1, 2024 shall provide coverage for all 4abortifacients, hormonal therapy medication, human 5immunodeficiency virus pre-exposure prophylaxis, and 6post-exposure prophylaxis drugs approved by the United States 7Food and Drug Administration, and follow-up services related 8to that coverage, including, but not limited to, management of 9side effects, medication self-management or adherence 10counseling, risk reduction strategies, and mental health 11counseling. This coverage shall include drugs approved by the 12United States Food and Drug Administration that are prescribed 13or ordered for off-label use for the purposes described in 14this Section. On or after the effective date of this 15amendatory Act of the 104th General Assembly, this coverage 16shall include pre-PrEP HIV screening, sexually transmitted 17infection screening, kidney function analysis, routine 18laboratory testing, and routine provider visits. 19    (c) The coverage required under subsection (b) is subject 20to the following conditions:21        (1) If the United States Food and Drug Administration 22    has approved one or more therapeutic equivalent versions 23    of an abortifacient drug, a policy is not required to 24    include all such therapeutic equivalent versions in its 25    formulary so long as at least one is included and covered 26    without cost sharing and in accordance with this Section.  10400HB2584ham002- 4 -LRB104 08321 BAB 24919 a1        (2) If an individual's attending provider recommends a 2    particular drug approved by the United States Food and 3    Drug Administration based on a determination of medical 4    necessity with respect to that individual, the plan or 5    issuer must defer to the determination of the attending 6    provider and must cover that service or item without cost 7    sharing.8        (3) If a drug is not covered, plans and issuers must 9    have an easily accessible, transparent, and sufficiently 10    expedient process that is not unduly burdensome on the 11    individual or a provider or other individual acting as a 12    patient's authorized representative to ensure coverage 13    without cost sharing.14    The conditions listed under this subsection (c) also apply 15to drugs prescribed for off-label use as abortifacients. 16    (d) Except as otherwise provided in this Section, a policy 17subject to this Section shall not impose a deductible, 18coinsurance, copayment, or any other cost-sharing requirement 19on the coverage provided. The provisions of this subsection do 20not apply to coverage of procedures to the extent such 21coverage would disqualify a high-deductible health plan from 22eligibility for a health savings account pursuant to the 23federal Internal Revenue Code, 26 U.S.C. 223.24    (e) Except as otherwise authorized under this Section, a 25policy shall not impose any restrictions or delays on the 26coverage required under this Section.  10400HB2584ham002- 5 -LRB104 08321 BAB 24919 a1    (f) The coverage requirements in this Section for 2abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), 3apply to a multistate plan that does not provide coverage for 4abortion.5    (g) If the Department concludes that enforcement of any 6coverage requirement of this Section for abortifacients may 7adversely affect the allocation of federal funds to this 8State, the Department may grant an exemption to that 9requirement, but only to the minimum extent necessary to 10ensure the continued receipt of federal funds.11(Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.) 12    Section 10. The Prior Authorization Reform Act is amended 13by adding Section 52 as follows: 14    (215 ILCS 200/52 new)15    Sec. 52. Prior authorization for certain prescription 16drugs; prohibited. A health insurance issuer may not require 17prior authorization for the following prescription drug types 18and their therapeutic equivalents approved by the United 19States Food and Drug Administration: human immunodeficiency 20virus pre-exposure prophylaxis and post-exposure prophylaxis 21medication or human immunodeficiency virus treatment 22medication. 23    Section 99. Effective date. This Act takes effect January   10400HB2584ham002- 6 -LRB104 08321 BAB 24919 a11, 2027.".